Identification of Celecoxib-Targeted Proteins Using Label-Free Thermal Proteome Profiling on Rat Hippocampus

Elham Gholizadeh, Reza Karbalaei, Ali Khaleghian, Mona Salimi, Kambiz Gilany, Rabab Soliymani, Ziaurrehman Tanoli, Hassan Rezadoost, Marc Baumann, Mohieddin Jafari, and Jing Tang

Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran (E.G., A.K.); Department of Psychology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania (R.K.); Physiology and Pharmacology Department, Pasteur Institute of Iran, Tehran, Iran (M.S.); Reproductive Immunology Research Center, Avicenna Research Institute, and Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran (K.G.); Medicum, Biochemistry/Developmental Biology and HI LIFE, Meilahti Clinic Proteomics Core Facility (R.S., M.B.), and Research Program in Systems Oncology, Faculty of Medicine (Z.T., M.J., J.T.), University of Helsinki, Helsinki, Finland; and Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran (H.R.)

Received December 3, 2020; accepted February 10, 2021

ABSTRACT

Celecoxib, or Celebrex, a nonsteroidal anti-inflammatory drug, is one of the most common medicines for treating inflammatory diseases. Recently, it has been shown that celecoxib is associated with implications in complex diseases, such as Alzheimer disease and cancer as well as with cardiovascular risk assessment and toxicity, suggesting that celecoxib may affect multiple unknown targets. In this project, we detected targets of celecoxib within the nervous system using a label-free thermal proteome profiling method. First, proteins of the rat hippocampus were treated with multiple drug concentrations and temperatures. Next, we separated the soluble proteins from the denatured and sedimented total protein load by ultracentrifugation. Subsequently, the soluble proteins were analyzed by nanoliquid chromatography tandem mass spectrometry to determine the identity of the celecoxib-targeted proteins based on structural changes by thermal stability variation of targeted proteins toward higher solubility in the higher temperatures. In the analysis of the soluble protein extract at 67°C, 44 proteins were uniquely detected in drug-treated samples out of all 478 identified proteins at this temperature. Ras-associated binding protein 4a, 1 out of these 44 proteins, has previously been reported as one of the celecoxib off targets in the rat central nervous system. Furthermore, we provide more molecular details through biomedical enrichment analysis to explore the potential role of all detected proteins in the biological systems. We show that the determined proteins play a role in the signaling pathways related to neurodegenerative disease—and cancer pathways. Finally, we fill out molecular supporting evidence for using celecoxib toward the drug-repurposing approach by exploring drug targets.

SIGNIFICANCE STATEMENT

This study determined 44 off-target proteins of celecoxib, a nonsteroidal anti-inflammatory and one of the most common medicines for treating inflammatory diseases. It shows that these proteins play a role in the signaling pathways related to neurodegenerative disease and cancer pathways. Finally, the study provides molecular supporting evidence for using celecoxib toward the drug-repurposing approach by exploring drug targets.

Introduction

Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties.

Celecoxib prevents the synthesis of lipid compounds called prostaglandins by selectively inhibiting cyclooxygenase (COX)-2 (Johnson et al., 2002; Schönthal, 2007). COX has an essential role in the synthesis of prostaglandins derived from arachidonic acid (Marnett et al., 1999). There are two isoforms of COX: COX-1 and COX-2. COX-1, as a gastric cytoprotectant, is physiologically constitutive and responsible for renal and platelet homeostasis. COX-2, which is considered to be inductive, arises only in situations of tissue trauma and infections (Perazella and Tray, 2001; Yaksh et al., 2001). All types of classic NSAIDs can inhibit both COX-1 and COX-2.

ABBREVIATIONS: BP, biologic process; CC, cellular component; CETSA, cellular thermal shift assay; CNS, central nervous system; COX, cyclooxygenase; DB, Drug Bank; DTC, Drug Target Commons; ER, endoplasmic reticulum; GO, gene ontology; HSP, heat shock protein; LC, liquid chromatography; MF, molecular function; MGI, Mouse Genome Informatics; MS, mass spectrometry; MS/MS, tandem MS; NSAID, nonsteroidal anti-inflammatory drug; PDP, Probes & Drugs portal; PTM, post-translational modification; Rab, Ras-associated binding protein; SERCA, sarcoplasmic/ER Ca2+-ATPase; SRP, signal-recognition particle; ST, Super Target; TPP, thermal proteome profiling.
isomers with a predominant effect on COX-1 (Smith et al., 2000). Most NSAIDs have broad side effects, such as bleeding, ulceration, and perforation on gastrointestinal tract, whereas celecoxib selectively inhibits COX-2 and does not have side effects on the digestive system (Rahme et al., 2007; Atukorala and Hunter, 2013). Since celecoxib suppresses pain and inflammation, it is one of the most commonly prescribed drugs and accounts for 5%–10% of prescriptions per year (Jones, 2001; Onder et al., 2004; Wongrakpanich et al., 2018). Celecoxib can easily access the central nervous system (CNS), whereas the mechanism of action through its protein targets in CNS has not yet been fully elucidated (Fond et al., 2014).

Determining the affinity of a drug for all its potential targets is the main challenge for understanding the mechanism of action in pharmaceutical sciences. Target-based drug discovery starts by identifying molecular targets, which are supposed to have an essential role in the disease of interest (Sams-Dodd, 2005; Schmidt, 2010; Schenone et al., 2013), opposed to phenotypic-based drug discovery. The mechanism of drug performance, which is essential for designing a drug, is not often considered in phenotypic-based drug discovery investigations (Swinney, 2013). However, target-based drug discovery research also has its limitations; for example, proving the presence of a protein target in a particular biologic pathway or its involvement in disease is a time- and cost-consuming process. Therefore, the development of alternative strategies for target deconvolution is on-demand. Different strategies have emerged, which are based on changes in target stability upon compound binding (Sjostrom et al., 2015; Li et al., 2016). Some successful options are stability of proteins from rates of oxidation (West et al., 2008; West et al., 2010; Strickland et al., 2013), drug affinity responsive target stability (Lomenick et al., 2011), cellular thermal shift assay (CETSA) (Martinez Molina et al., 2013), and thermal proteome profiling (TPP) (Savitski et al., 2014). In stability of proteins from rates of oxidation, proteins are subjected to an increasing concentration of a chemical denaturant (hydrogen peroxide) and then the evaluation of oxidized methionine in unfolded proteins. The folding free energy is then calculated based on the denaturant concentration in the presence and absence of ligands to evaluate protein-ligand affinities. Drug affinity responsive target stability is based on the modification- or immobilization-free limited proteolysis after the binding of a ligand to proteins. This is in accordance with the assumption that protein targets become less susceptible to proteolysis when it is drug-bound and not drug-free, especially the exposed part of the protein, which is protected from protease. In CETSA, changes in the thermal stability of proteins are used for studying the ligand-binding process. However, CETSA can only detect a small number of protein changes since it is limited to an antibody readout. However, the CETSA principles can be combined with mass spectrometry–based proteomics to provide an unbiased identification of more comprehensive drug-protein interactions in a single experiment (Larance and Lamond, 2015; Aebersold and Mann, 2016). TPP, a recently suggested method, can be done in high throughput to identify drug targets (Reckzeh et al., 2019). It can also be applied in living cells in addition to in vitro studies without requiring compound labeling. It is an approach that combines CETSA and quantitative mass spectrometry, enabling monitoring of changes in protein thermal stability across heat scaling up. Identifying drug targets in TPP is based on changes in the thermal stability of proteins after their binding to the substrates (i.e., drugs) (Pace and McGrath, 1980; Vedadi et al., 2006). This stability is mostly related to the protein melting temperature, a temperature at which the process of unfolding will happen (Jarzab et al., 2020).

Thermal stress usually causes some irreversible changes in the structure of a protein leading to unfolding. This process leads to the exposure of the hidden hydrophobic core of a protein and, finally, to its aggregation (Kurganov et al., 2002; Asial et al., 2013). For proteins connected to a ligand (e.g., a drug), more energy is needed for unfolding because the dissociation of a ligand from the protein requires some energy itself (Pace and McGrath, 1980). In other words, binding of a ligand to a protein causes the formation of a complex with increased stability compared with the free protein. Therefore, these proteins are more resistant to the process of unfolding induced by heat, a fact that is the basis of TPP (Savitski et al., 2014; Franken et al., 2015; Reinhard et al., 2015; Becher et al., 2016). TPP can be used to investigate any change in the structure of the protein (Franken et al., 2015). TPP is unique in having the following advantages: Although it does not require any labeling, it can be applied to living cells, and it permits an objective search of drug targets (Mateus et al., 2017).

In the present study we have investigated targets of celecoxib, a high-prevalence drug, using a label-free TPP method in rat hippocampus. We also provide supporting computational evidence related to biologic annotations of the targets to explain the potential repurposing implications of this NSAID (Zagidullin et al., 2019; Tanoli et al., 2020). We further show that several proteins related to cancer and inflammation pathways are the targets of celecoxib. The results of these experiments are also compared with the available knowledge across all drug-target interaction databases. In addition to reinforcing previous findings, we especially explore more potential off targets of celecoxib within the nervous system. Based on these results, we suggest a conceivable repurposing strategy of this drug for neuronal inflammation as well as cancer.

Materials and Methods
Preparation Rat Brain for Protein Extraction. Five rats were used as biologic replicates to not affect the present study by two crucial variables (i.e., sex and weight). Therefore, five male rats of Rattus norvegicus were prepared by the weight of 200 ± 10 g. After dissecting the hippocampus under complete anesthesia, tissue was washed two times with cold PBS. Experiments were approved by the local Animal Ethics Committee (National Institute for Medical Research Development Ethics Board, National Institute for Medical Research Development of Iran, 964580). Immediately after washing, the hippocampus was homogenized and lysed in RIPA buffer (NaCl, Triton 500, Na deoxycholate, Tris HCl, Protease Inhibitor Cocktail pH−7.4). Then, the homogenates were centrifuged at 20,000g for 20 minutes at 4°C to separate the protein extracts from precipitates (Pei et al., 2007). Bradford assay was used to measure protein concentrations.

Drug Treatment and Heating Procedure. A solution of celecoxib in DMSO was added to the protein extracts to have a 0.1% final-DMSO concentration. In this study, five concentrations of celecoxib including 20, 10, 5, 1, and 0.1 μM were used, based on the pharmaceutical
implications as described previously (Paulson et al., 2001; Dembo et al., 2005; Kang et al., 2009; Wang et al., 2017). Two negative controls (i.e., control with DMSO and control with pure double distilled water) were also used. The starting protein amounts in each tube were 1600 μg in total of 400 μl solution. The extracts were incubated for 10 minutes at 23°C and then divided into 4 aliquots of 100 μl. These 4 aliquots were heated for 3 minutes at the following temperatures: 37°C, 47°C, 57°C, and 67°C. This was followed by cooling down at room temperature for 3 minutes. Subsequently, the extracts were centrifuged at 60,000g for 30 minutes at 4°C, and finally, the supernatant that contained soluble targeted proteins was collected and stored at −20°C for further investigations as previously described (Jafari et al., 2014; Savitski et al., 2014).

**Sample Preparation, Proteolytic Digestion, and Nano-Liquid Chromatography–Electrospray Ionization–Tandem Mass Spectrometry.** Next, the extracted proteins treated with the highest drug concentration (i.e., 20 μM at the highest temperature, 67°C) were selected for the protein identification step. The highest dosage of celecoxib and the highest temperature were used to avoid detection of the weak or transient interactions of celecoxib and the proteins. The same temperature was used to analyze and identify proteins in the control negative samples.

The protein samples were digested in Amicon Ultra-0.5 centrifugal filters using a modified filter-aided sample preparation method (Wisniewski et al., 2009; Scifo et al., 2015). In brief, reduction and alkylation of samples was performed by the addition of tri(2-carboxyethyl)phosphine and iodoacetamide to final concentrations of 2 and 50 mM, respectively, and this was followed by incubation in the dark for 30 minutes. The trypsin solution was resuspended in 1% trifluoroacetic acid and sonicated in a water bath for 1 minute before injection. Fractionated protein digests were analyzed in nano-LC–Thermo Q Exactive Plus Orbi-Trap MS. Each sample run was followed by two empty runs to wash out any remaining peptides from previous runs. The peptides were separated by Easy-nLC system (Thermo Scientific) equipped with a reverse-phase trapping column Acclaim PepMapTM 100 (C18, 75 μm × 20 mm, 3-μm particles, 100 Å; Thermo Scientific), and this was followed by an analytical Acclaim PepMapTM 100 RSLC reversed-phase column (C18, 75 μm × 250 mm, 2-μm particles, 100 Å; Thermo Scientific). The injected sample analyses were trapped at a flow rate of 2 μl/min in 100% of solution A (0.1% formic acid). After trapping, the peptides were separated with a linear gradient of 120 minutes comprising 96 minutes from 3% to 30% of solution B (0.1% formic acid/80% acetonitrile), 7 minutes from 30% to 40% of solution B, and 4 minutes from 40% to 95% of solution B.

LC-MS data acquisition was done with the mass spectrometer settings as follows: the resolution was set to 140,000 for MS scans and 17,500 for the MS/MS scans. Full MS was acquired from 350 to 1400 m/z, and the 10 most abundant precursor ions were selected for fragmentation with 30 seconds dynamic exclusion time. Ions with 2+, 3+, and 4+ charge were selected for MS/MS analysis. Secondary ions were isolated with a window of 1.2 m/z. The MS automatic gain control target was set to 3 × 106 counts, whereas the MS/MS automatic gain control target was set to 1 × 105. Dynamic exclusion was set with a duration of 20 seconds. The Normalized Collision Energy stepped was set to 28 kJ mol⁻¹.

**Proteomic Data and Bioinformatic Analysis.** After LC-MS/MS acquisition, the raw files were qualitatively analyzed by Proteome Discoverer, version 2.4.0.305 (Thermo Scientific). The identification of proteins by Proteome Discoverer was performed against the UniProt Rat protein database (release 11-2019 with 8086 entries) using the built-in SEQUEST HT engine. The following parameters were used: 10 ppm and 0.25 Da were the tolerance values set for MS and MS/MS, respectively. Trypsin was used as the digesting enzyme, and two missed cleavages were allowed. The carbamidomethylation of cysteines was set as a fixed modification, whereas the oxidation of methionine and deamidation of asparagine and glutamine were set as variable modifications. The false discovery rate was set to less than 0.01, and a minimum length of six amino acids (one peptide per protein) was required for each peptide hit.

After the identification of proteins, for better understanding of the role and importance of proteins, enrichment analysis was used to determine the corresponding biologic processes (BPs) by EnrichR (Chen et al., 2013). Eight different libraries were selected to explore biomedical annotations of drug targets, including gene ontology (GO), molecular function (MF), GO cellular component (CC), GO BP, DisGeNet (Piñero et al., 2017), HumanPhen (Köhler et al., 2019), Mouse Genome Informatics (MGI) (Eppig et al., 2017), PheWeb (Gagliano Talian et al., 2020), and WikiPathways (Kutmon et al., 2016). We used EnrichR’s combined scores and adjusted p values to sort annotations in descending fashion. Also, Post-translational modification Enrichment, Integration and Matching ANalysis (PEIMAN) software was used to determine possible enriched post-translational modifications (PTMs) in the list of protein targets (Nickichi et al., 2015).

**Statistical Analysis.** All data were analyzed using R (version 4.0.3) with RStudio (Free Software Foundation Inc., Boston, MA). Unless otherwise noted, data are showed as mean ± S.D. for technical replicates. Statistical significance was calculated by Fisher’s exact test and hypergeometric test for enrichment analysis. Multiple testing corrections were done using the Benjamini-Hochberg method (Jafari and Ansari-Pour, 2019). Using the decoy database search feature, the q-value for protein identification was calculated in Proteome Discoverer software. Because of the exploratory nature of this study, we reduced biologic variability by pooling the rat samples and focused on the physicochemical effect of celecoxib treatment on extracted proteins from the rat hippocampus. Hence, testing a null hypothesis among rats is irrelevant, and the statistical tests’ outcomes are interpretable based on technical replicates in each step of our study.

**Results**

The amount of soluble proteins significantly decreased with increasing temperature (Supplemental File 1). The declining pattern was observed for all five drug concentrations: 20, 10, 5, 1, and 0.1 μM as well as two negative controls (i.e., water and DMSO). Finally, the protein sample treated in 20-μM drug concentration and 67°C was chosen for further analysis. In fact, proteins start unfolding at high temperature unless the binding energy of any binding partner, such as a drug, is high enough (Petsko and Ringe, 2004). We used the highest temperature to avoid detecting the weak and transient interactions among celecoxib and the proteins. Also, we selected the highest dosage of celecoxib to detect all potent drug-target interactions.

A comprehensive comparison of identified proteins in samples treated with celecoxib and two controls is shown in Fig. 1 and Fig. 2A. These proteins were soluble at 67°C after the treatment in 20-μM celecoxib, water, and DMSO, respectively, and finally detected by nano-LC–Thermo Q Exactive Plus Orbi-Trap MS. Water control treatment contained only protein samples without any other additional substances, and 351 proteins were detected in this subset. Also, 378 proteins were identified in the DMSO treatment (other negative control). Furthermore, 357 proteins were detected in the drug-treated sample, in which 44 proteins were specific to the treatment. The highest dosage of celecoxib and the highest temperature were used to avoid detection of the weak or transient interactions of celecoxib and the proteins. Also, we identified negative control proteins with celecoxib and two controls (i.e., control with DMSO and control with pure double distilled water). Finally, the protein sample treated in 20-μM drug concentration and 67°C was chosen for further analysis. In fact, proteins start unfolding at high temperature unless the binding energy of any binding partner, such as a drug, is high enough (Petsko and Ringe, 2004). We used the highest temperature to avoid detecting the weak and transient interactions among celecoxib and the proteins. Also, we selected the highest dosage of celecoxib to detect all potent drug-target interactions.
across the high temperature (Usman et al., 2014). The identified HSPs were shared with other groups, such as HSP90-β and 60-kDa mitochondrial heat shock protein. Thus, we could infer that HSPs are not the particular target of celecoxib.

We also examined the previously known targets of celecoxib according to five drug-target databases for all species (Fig. 2B), including R. norvegicus (rat) in particular (Fig. 2C). Then, we compared the TPP-identified proteins with the known targets of this drug in rats. Out of 242 already-identified celecoxib targets for 24 species in all five databases, only 21 proteins were found in rat. Figure 2, B and C show the total number of proteins in each set by the horizontal bar plots. The vertical bar plot indicates the number of proteins in each database uniquely and the different set of the intersections sorted by the frequency of targets. In this analysis, we selected five well-known drug-target databases [i.e., Drug Bank (DB) (Wishart et al., 2018), Super Target (ST) (Hecker et al., 2012), Probes & Drugs portal (PDP) (Skuta et al., 2017), Chembl (Bento et al., 2014), and Drug Target Commons (DTC)] (Tang et al., 2018; Tanoli et al., 2018). The DB database shows five targets for celecoxib, of which one was related to the rat. The ST and PDP databases suggest 41 and 45 proteins as targets of celecoxib, of
which three and five are expressed in the rat, respectively. Searching in DTC and Chembl databases introduced 168 and 203 proteins in 24 species as celecoxib targets, and 17 and 16 of them are specified in the rat, respectively. In total, around 70% of the identified targets are related to human proteins, and the proportion of rat-specific proteins is much lower, especially if we consider each database independently. It implies the lack of complete information in rat species databases, avoiding a more comprehensive celecoxib target profile in rats. It should be considered that most of the introduced protein targets are associated with the COX protein family and are involved in NSAID-related pathways like the inflammatory process, which is the explicit indication of this drug.

As shown in Fig. 2B, the intersection of all databases contains only two human proteins (i.e., 3-phosphoinositide–dependent protein kinase 1, carbolic anhydrase 2, and one rat protein, prostaglandin-endoperoxide synthase 2) because of the cross reference of the resources. Chembl and DTC are the most comprehensive drug-target bioactivity resources based on manual curation (more than 1.9 million chemicals and 13,000 protein targets); therefore, it was expected that they have the highest number of intersected proteins for celecoxib. At the same time, the other databases used experimental evidence to explore targets of drugs. Only six proteins have been identified as celecoxib targets using ST, DB, and PDP so far. On the other hand, the main subject of celecoxib studies is to study the effects of this drug on the heart and circulatory system; hence, researchers focused on exploring new off targets on related organs and tissues. Although celecoxib can simply pass through the blood-brain barrier, its impacts on the brain and CNS have not been well described. Here, we focused on a minute part of CNS (i.e., the hippocampus); hence, we did not anticipate to observe a high proportion of intersected protein targets with the other databases. However, we found a Ras-associated binding protein (Rab)-2A to be a shared celecoxib-targeted protein between TPP-identified proteins and the PDP database. The high amount

Fig. 2. (A) The Venn diagram of identified proteins of rat hippocampus proteome recovered by TPP technique in three groups: treated with DMSO, H2O, and celecoxib (20 μM). (B) Drug-target database comparison based on celecoxib-targeted proteins within diverse species. In this inset plot, intersections between the databases are illustrated. The horizontal bar plot shows the total number of proteins in each database. The vertical bar plot indicates the number of proteins in each database uniquely and the different sets of the intersections. DB, ST, Drug Central (DC), PDP, and DTC are represented in this plot. The inset plot displays the characterized species in the mentioned databases. We scaled the word size by their frequency of corresponding protein targets of celecoxib in each species independently. (C) Rat-specific drug-target database comparison based on celecoxib-targeted proteins along with the TPP-identified proteins. (D) Homology network of TPP-identified proteins and reported targets of celecoxib in drug-target databases. The identified proteins in the present study are shown with a red triangle, and the proteins introduced by the databases are displayed with green circles. The thickness of the edges indicates the identity percentage of protein sequences in this study.
of expression of Rab-2A in the whole brain has been previously reported (Palasca et al., 2018), which was helpful for our study (Fig. 2; Supplemental File 3). This protein can be a clue to explain the association of celecoxib with cancer-related pathways since Rab-2A is a cancer driver gene product, and it plays a role in promoting tumorigenesis (Luo et al., 2015).

We also investigated the homology of TPP-identified proteins with reported celecoxib targets to explore structural similarities (Fig. 2D). The overall similarity of amino acid sequences in both protein groups was represented using a protein homology network. In this graph, the thickness of the edges indicates the amino acid identity percentages. There were 665 and 3138 pairwise similarities with more than 25% and 10% thresholds. Thus, it can be concluded that several of TPP-identified proteins have a close homology with the previously reported celecoxib-targeted proteins.

Furthermore, to characterize the related biologic functions of the TPP-identified proteins, we implemented gene-enrichment analysis using disease- and pathway-related resources available in EnrichR (Fig. 3). The enriched annotations in DisGeNet database include muscular stiffness with the lowest adjusted P value. Neurodegenerative diseases, such as Alzheimer disease and epilepsy, and breast cancer–related annotations are also highly enriched in these proteins. Therefore, it can be a clue for celecoxib to be a potential choice for add-on therapy in these diseases. We also assessed other resources, such as MGI, HumanPhen, and PheWeb, for exploring enriched phenotypic annotations in the TPP-identified list of 44 proteins. In these databases, terms such as “Broad head,” “increased motor neuron number,” “Schizophrenia,” “psychotic disorders,” “acquired hemolytic anemias,” and “abnormal thrombopoiesis” showed the lowest adjusted P values. In the perspective of pathway enrichment analysis, mRNA processing, such as cytoplasmic ribosomal proteins and splicing factor Nova, regulated synaptic proteins, which were also enriched along with cancer-related pathways, such as interleukin-3, PI3K-Akt-mTOR, and G protein–mediated signaling pathways, which have an importance in cancer, inflammation, and neurodegenerative diseases.

In Fig. 4 and Supplemental File 4, the enriched gene ontology annotations (i.e., BPs, CCs, and MFs) were summarized by using semantic similarity. The annotations of BP were divided into six major subsets (; Supplemental File 4A). The signal-recognition particle (SRP)-dependent cotranslational protein targeting to membrane processes contributes to the prominent concept in this analysis. This process is responsible

---

**Fig. 3.** Enrichment analysis of TPP-identified proteins as the targets of celecoxib in the rat hippocampus. This plot indicates enriched annotations related to disease, phenotypes, and biologic pathways of celecoxib-targeted proteins. Each panel distinctly represents the annotations of gene-disease associations (DisGeNET), Human Phenotype Ontology (HumanPhen), MGI, UKBiobank PheWeb, and WikiPathway. These annotations are displayed with the negative of logarithmic P values of Fisher’s exact test and combined scores based on EnrichR webtool. GPCR, G protein–coupled receptor; HIV, human immunodeficiency virus; PI3K-Akt-mTOR, phosphatidylinositol 3-kinase–protein kinase B–mammalian target of rapamycin.
for the targeting of proteins to the cell membrane during translation, and it is dependent on two key components: the SRP and the SRP receptor. Rab protein signal transduction is the second most prevalent annotation in the treemap of BPs. Rab proteins represent the largest branch of the Ras-like small GTPase superfamily, alternating between GTP- and GDP-bound states and releasing a series of molecular signals within the cell. Nuclear-transcribed mRNA catabolism, nonsense-mediated decay, post-translational protein modification, and neutrophil-mediated immunity are four other groups of annotations in BP similar to the result of pathway enrichment analysis. These terms indicate the long-term effects of celecoxib by PTM-related mechanisms and G protein–related signaling pathways. At the molecular level, nine groups of MF annotations were illustrated for TPP-identified proteins (Fig. 4; Supplemental File 4B). The activities related to signal transduction in neuronal cells involving transport mechanisms were also highlighted, such as myosin, actin, and cadherin binding, in addition to GDP binding and GTPase activity. The enriched annotations of CC are mainly corresponding to the cytosolic part, which also underscores altering the signaling pathways (Jafari et al., 2013) (Fig. 4; Supplemental File 4C).

The enriched PTMs in TPP-identified proteins were also evaluated by PEIMAN software. It is presumed that soluble proteins at 67C might be enriched in any of PTMs to last longer under temperature changes. We observed 15 enriched PTMs, which emphasizes the role of PTMs in the thermostability of proteins. For example, acetylation, prenylation, and phosphorylation are significantly detected in all TPP-identified proteins. Citrullination was the specific PTM for celecoxib targets that was statistically enriched by adjusted P value 0.0076. All of the enriched PTMs were confirmed by researching the proteomic data using these PTMs as variable modifications in Proteome Discoverer.

Discussion

Celecoxib is one of the top-selling NSAID medicines in the world. Also, NSAIDs involve 5%–10% of the remedy of all prescriptions per year (Paulson et al., 2001; Onder et al., 2004). There are some reports that show the possible indication of celecoxib with the neurodegenerative diseases associated with inflammatory processes (Akiyama et al., 2000; Hirsch et al., 2003; (Eikelenboom and van Gool, 2004) Eikelenboom and Van Gool, 2004; McGeer and McGeer, 2004; Terzi et al., 2018). Although celecoxib can pass through the blood-brain barrier and access the CNS, reports about side effects of celecoxib (Goncalves et al., 2010; Nam et al., 2015) are related to cardiovascular diseases rather than the nervous system (Fond et al., 2014). In other words, the major molecular footprints of this medicine on CNS are not well described (Fond et al., 2014). Indeed, as we expected, we observed that most of the introduced targets of celecoxib in different
One of the identified celecoxib targets is Rab-2A, which is a GTPase required for protein transport from the endoplasmic reticulum (ER) to the Golgi complex by regulating coat protein–dependent vesicular transport (Gaudet et al., 2011; Haas et al., 2007). This protein was common between TPP-identified targets and the PDP database (Fig. 2C). PDP is a powerful up-to-date web resource that unifies various commercial and public bioactive compound libraries (Skuta et al., 2017). To explore the role of Rab2A in detail, Sugawara et al. (2014) studied the effect of Rab2A knockdown on glucose-stimulated insulin secretion and the Golgi intermediate compartment in the corresponding cells. They reported that inactivation of Rab2A mitigated glucose-induced ER stress and inhibited apoptosis induced by ER stress through enlarging of the ER-Golgi intermediate compartment (Sugawara et al., 2014). Therefore, it seems that celecoxib is associated with apoptosis by targeting Rab-2A and implicating ER stress. Providing more evidence through testing celecoxib on the same cells—insulinoma cells—to clarify the celecoxib influence on the ER stress is warranted.

Also, TPP-identified proteins were enriched in pathways related to neurodegenerative disease and cancer. Interestingly, the anticancer activity of celecoxib has been reported in various models of animal tumors, and it is proposed that this drug is beneficial for the prevention and treatment of cancer (Masferrer et al., 2000; Dannenberg and Subbaramaiah, 2003; Koehne and Dubois, 2004). The molecular mechanisms of antitumoral effects of celecoxib have become a challenging issue, since some reports showed that the effect of celecoxib on cancer is apart from COX-2 inhibition, meaning that celecoxib has other targets than COX-2 (Kashfi and Rigas, 2005; Grösch et al., 2006; Schönthal, 2007). Several components as intermediate candidates have been proposed for the anticancer effects of celecoxib, the most common of which is the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) (Johnson et al., 2002; Tanaka et al., 2005; Pyrko et al., 2007). Our CC enrichment analysis also disclosed that the endoplasmic reticulum lumen annotation was statistically enriched in TPP-identified proteins, such that several of the proteins involved in the pathways that regulate calcium concentrations, including endoplasmic reticulum oxidoreductase 1α, arylsulfatase B, nucleolar protein 3, stromal interaction molecule 1, calcitonin receptor, stromal cell–derived factor 4, and bel-2–like protein 4 (Fig. 4). Interestingly, it has been previously shown that celecoxib increases the intracellular concentration of calcium by inhibiting SERCA (Johnson et al., 2002; Wang et al., 2004; Tanaka et al., 2005; Pyrko et al., 2007), and the long-term leakage of calcium from the endoplasmic reticulum acts as a potent stimulant of ER stress, which finally leads to cell death and exerts its effect on cancer (Kim et al., 2007; Pyrko et al., 2007).

Several members of the Rab family are obviously expressed in various cancer tissues, and dysregulation of Rab expression could be tumorigenic or tumor-suppressive (Chia and Tang, 2009). The Rab family plays an essential role in multiple aspects of membrane-trafficking control. Therefore, vesicle transport regulators play crucial roles in the mediation of cancer cell biology, including uncontrolled cell growth, invasion, and metastasis. The Rabs like other members of the Ras superfamily function as molecular switches through changes in their guanine nucleotide-binding status between the active GTP-bound and inactive GDP-bound forms. In its active GTP-bound form, Rabs could mediate vesicular transport by allowing transport carriers or vesicles to engage specific effectors, such as motor proteins and tethering factors as well as vesicle fusion with the engagement of soluble N-ethylmaleimide–sensitive factor (Zhao et al., 2007) attachment receptor (Hong, 2005; Ungermann and Langosch, 2005) proteins. Vesicle delivery and dynamics are critical for regulating cell behavior associated with cell migration/invasion and tumorigenesis. Cooperation between Rabs and effectors in mediating vesicle movement pathways has significant influence on tumor progression and malignancy. Therefore, it raises the possibility that targeting a particular trafficking system may provide a new approach to cancer treatment (Tseng and Wang, 2016). As shown in this study, celecoxib-targeted proteins (i.e., RAB2A, RAB10, and RAB11B) are notably involved in Rab protein signal transduction. As shown in Fig. 4B, TPP-identified proteins are enriched in GDP binding, GTPase activity, and protein phosphatase inhibitor activity that change the GTPases and, as a result, are involved in mechanisms associated with cancer. Therefore, it seems that studying the effect of celecoxib on cancer models by TPP provides more supporting evidence.

Neurodegenerative diseases are also assigned to TPP-identified targets of celecoxib as an anti-inflammatory drug. Recent studies demonstrated that neuronal inflammation is a vital trigger of neurologic diseases (Terzi et al., 2018), and it exacerbates disorders, including Alzheimer, Parkinson, and Huntington diseases as well as amyotrophic lateral sclerosis and multiple sclerosis (Akiyama et al., 2000; Hirsch et al., 2003; McGeer and McGeer, 2004; Eikelenboom and Van Gool, 2004). In the present study, some of the mentioned neurodegenerative disorders were enriched based on phenotypic-based biologic annotations, such as schizophrenia and depression. Twelve of 44 TPP-identified celecoxib targets are involved in Alzheimer disease metabolism, suggesting a high possibility of celecoxib involvement in the mechanisms of this neurodegenerative disease. Notably, inflammation of the nervous system is observed in these disorders, and it is accompanied by an increase in inflammatory cytokines (Philips and Robberecht, 2011; Agius, 2012; Morales et al., 2015). We also illustrated that celecoxib could be beneficial in treating the diseases mentioned above that are associated with inflammation by affecting the biosynthesis pathway of prostaglandins by the involvement of four identified proteins (i.e., dynactin subunit 1, PSIP1, bel-2–like protein 4, and AMPH).

Finally, we describe the importance of PTMs for the thermal stability of proteins. We show that multiple PTMs are involved in the protein thermostability. For example, acetylation, which significantly affects the life span of intracellular proteins by avoiding intracellular proteases degradation, is enriched in all TPP-identified proteins (Zhou et al., 2016; Lahusen et al., 2018). Citrullination is the specific PTM identified in celecoxib-treated sample (see Fig. 5). It is related to the change of arginine to citrulline, which strongly affects the structure and function of proteins in both physiologic and pathologic processes, such as apoptosis, multiple sclerosis, and Alzheimer disease (György et al., 2006; Acharya et al.,
treating cancer by inhibiting SERCA and increasing the intracellular concentration of calcium, which causes ER stress along with cell death. This is another proposed mechanism affecting the trafficking system since transport regulators play essential roles in the mediation of cancer cell biology and especially circulating tumor cells. We found a significant effect of this medicine on proteins involved in the trafficking system of cells.

On the other hand, neuronal inflammation is a major culprit of neurodegenerative diseases, wherein proteins were significantly enriched in the present study. Inflammation in CNS starts by stimulation of astrocytes, and it continues with entering environmental immune cells to the brain. This process causes overproduction of cytokines, nitric oxide, active oxygen species, and prostaglandins and eventually damages and causes death of neurons (Philips and Robberecht, 2011; Nam et al., 2015; Wang et al., 2017; Terzi et al., 2018). Our findings support the idea of using celecoxib for neuronal inflammation because of the explored association of celecoxib targets and the inflammation.

To conclude, we identified several novel celecoxib protein targets using TPP, which could be of interest in modifying several pathways in CNS. Our findings provide new molecular evidence for celecoxib to be used as an add-on therapy in neurodegenerative disorders and cancer. However, more preclinical and paraclinical evidence is required to suggest the true drug-repurposing potential of celecoxib. In general, the potential drug targets can be corroborated by functional studies. Our findings can be considered in different pathological conditions, such as animal models with neurodegenerative disease or cancer with high COX protein family expression and other inflammatory proteins. In the case of providing enough amount of purified protein target, the kinetics and affinities of the drug-target interactions can also be evaluated using various biophysical methods, such as isothermal titration calorimetry and surface plasmon resonance. All told, additional supporting evidence using the possible protein-specific strategies, such as antibody-based and activity-based assays, can support the rationale of celecoxib repositioning.

Acknowledgments
The authors also acknowledge Dr. Rozbeh Jafari and Dr. Farnaz Barneh for helpful comments.

Authorship Contributions
Participated in research design: Baumann, Jafari, Tang.
Conducted experiments: Gholizadeh, Karbalaei, Soliymani.
Contributed new reagents or analytic tools: Khaleghian, Salimi, Gilany, Tanoli, Rezadoost, Baumann.
Performed data analysis: Gholizadeh, Soliymani, Rezadoost, Jafari.
Wrote or contributed to the writing of the manuscript: Gholizadeh, Baumann, Jafari, Tang.

References